The cohort is heavily skewed to patients receiving granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood and a cyclophosphamide-based GVHD prophylaxis regimen as both conditions are standard at our clinic (table S1). This evidence concerns the gene CSF3 and graft versus host disease.